Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Encore Vision Inc.

Headquarters: Fort Worth, TX, United States of America
Website: N/A
Year Founded: 2000
Status: Acquired

BioCentury | Oct 25, 2022
Regulation

Oct. 25 Quick Takes: FDA approves J&J’s Tecvayli, first bispecific T cell engager for MM

Plus: Novartis prunes programs and updates from Ipsen, Biogen, Astellas-Taysha, Alto, AZ and more
BioCentury | Jun 17, 2021
Emerging Company Profile

Lenz: focused on an eye drop for age-related farsightedness

Emerging Company Profile: With Versant, RA Capital-backed $47M series A, Lenz eyes pivotal study for presbyopia program
BioCentury | Sep 16, 2017
Strategy

Passing the baton

Challenges and opportunities for Novartis’ CEO designate Narasimhan
BioCentury | Jan 6, 2017
Company News

Encore Vision, Novartis deal

BioCentury | May 16, 2016
Clinical News

EV06: Phase I/II data

BioCentury | Feb 1, 2016
Clinical News

EV06: Completed Phase I/II enrollment

BioCentury | Oct 12, 2015
Clinical News

EV06: Phase I/II started

Items per page:
1 - 7 of 7